Patents Assigned to Nanocarrier Co., Ltd.
-
Publication number: 20210260207Abstract: The present invention provides a polyion complex which can efficiently deliver mRNA into a living body as well as a therapeutic agent and a therapeutic method of arthropathy in which the polyion complex is used. For example, there is provided a polyion complex comprising a cationic polymer and mRNA, wherein the cationic polymer is a polymer comprising a cationic unnatural amino acid as a monomer unit and the cationic unnatural amino acid is an amino acid having a group represented by —(NH—(CH2)2)p—NH2, wherein p is 2, 3 or 4, as a side chain.Type: ApplicationFiled: April 26, 2021Publication date: August 26, 2021Applicant: NanoCarrier Co., Ltd.Inventors: Keiji ITAKA, Shinsuke OHBA, Yuichi TEI, Kazunori KATAOKA
-
Patent number: 11020418Abstract: A unit structure-type pharmaceutical composition includes a single nucleic acid, such as an antisense nucleic acid, electrostatically bound to a single block copolymer having a cationic polyamino acid segment and a hydrophilic polymer chain segment. The negative charges of the nucleic acid are counterbalanced, at least substantially, by the positive charges of the cationic polyamino acid segment such that the pharmaceutical composition is electrically neutral or nearly electrically neutral. Further, the nucleic acid is covered with the hydrophilic polymer chain segment. The block copolymer thereby improves the blood retention capability of the nucleic acids.Type: GrantFiled: October 5, 2017Date of Patent: June 1, 2021Assignees: NANOCARRIER CO., LTD., THE UNIVERSITY OF TOKYOInventors: Kazunori Kataoka, Kanjiro Miyata, Nobuhiro Nishiyama, Kensuke Osada, Sumiyo Watanabe, Shigeto Fukushima, Hiroyuki Chaya, Hiroyasu Takemoto, Yasuki Kato
-
Patent number: 9920133Abstract: Monoclonal antibodies against human and mouse tissue factor, and fragments thereof, are disclosed, as well as pharmaceutical compositions and compositions for drug delivery containing the same. Therapeutic methods using the same are also disclosed.Type: GrantFiled: February 3, 2015Date of Patent: March 20, 2018Assignees: NATIONAL CANCER CENTER, The University of Tokyo, RIKEN, NanoCarrier Co., Ltd.Inventors: Yasuhiro Matsumura, Masahiro Yasunaga, Yoshikatsu Koga, Yoshiyuki Yamamoto, Ryuta Sato, Ryo Tsumura, Kazunori Kataoka, Nobuhiro Nishiyama, Yutaka Miura, Shino Manabe, Yasuki Kato
-
Publication number: 20180015007Abstract: A polymeric micelle carrier composition contains i) a block copolymer having a hydrophilic polymer chain segment and a hydrophobic polymer chain segment; ii) a charged surfactant; and iii) a fatty oil. The carrier composition can be utilized as a base material of a cosmetic composition or a pharmaceutical composition and excels in loadability of non-lipophilic drugs. One example of a non-lipophilic drug is a hair growth promoting peptide.Type: ApplicationFiled: February 29, 2016Publication date: January 18, 2018Applicant: NanoCarrier Co., Ltd.Inventors: Kenta ISHII, Yasuki KATO
-
Patent number: 9808480Abstract: A unit structure-type pharmaceutical composition includes at least one nucleic acid, such as siRNA, electrostatically bound to at least one block copolymer having a cationic polyamino acid segment and a hydrophilic polymer chain segment. The negative charge(s) of the nucleic acid are counterbalanced, at least substantially, by the positive charge(s) of the cationic polyamino acid segment such that the pharmaceutical composition is electrically neutral or nearly electrically neutral. Further, the nucleic acid is covered with the hydrophilic polymer chain segment(s). The at least one block copolymer thereby improves the blood retention capability of the nucleic acid(s).Type: GrantFiled: April 30, 2013Date of Patent: November 7, 2017Assignees: NANOCARRIER CO., LTD., THE UNIVERSITY OF TOKYOInventors: Kazunori Kataoka, Kanjiro Miyata, Nobuhiro Nishiyama, Kensuke Osada, Sumiyo Watanabe, Shigeto Fukushima, Hiroyuki Chaya, Hiroyasu Takemoto, Yasuki Kato
-
Patent number: 9795563Abstract: The present invention provides a particulate pharmaceutical composition which has improved drug encapsulation stability and is suitable for a drug delivery system. The particulate pharmaceutical composition 1 contains: a plurality of block copolymer unit 2 arranged radially, each of which has a hydrophobic polymer-chain segment 2b, which is arranged radially inside, and a hydrophilic polymer-chain segment 2a, which is arranged radially outside; a drug 4, which includes a biomacromolecule; and a charged lipid 3, which has an electrical charge opposite to that of the drug 4; wherein the charged lipid 3 is being attracted to the hydrophobic polymer-chain segment 2b, and the drug 3 is positioned radially inside the hydrophobic polymer-chain segment 2b. The pharmaceutical composition 1 can effectively prevent the drug 4 from disengaging from the particle.Type: GrantFiled: November 2, 2015Date of Patent: October 24, 2017Assignee: Nanocarrier Co., Ltd.Inventors: Atsushi Ishii, Yasuki Kato
-
Patent number: 9561284Abstract: A pharmaceutical composition includes a block copolymer having a hydrophilic segment, a hydrophobic segment, and a boronic acid compound bound to a side chain of the hydrophobic segment via a linker moiety that includes a heterocyclic structure. The heterocyclic structure contains a cyclic skeleton that includes a boron atom of the boronic acid compound, one or two atom(s) X bound to the boron atom and selected from an oxygen atom and a nitrogen atom, and one or two carbon atom(s) (respectively) bound to the atom(s) X. The block copolymer further includes at least one organic group bound to the carbon atom(s). The organic group(s) contain(s) an aromatic group or cyclic alkyl group that sterically protects a boronic acid ester bond and/or a boron amide bond resulting from bonding between the boron atom and the atom(s) X.Type: GrantFiled: April 2, 2012Date of Patent: February 7, 2017Assignee: NANOCARRIER CO., LTD.Inventors: Hiroyuki Saito, Katsutoshi Kobayashi, Ryosuke Tanaka, Mitsunori Harada, Yasuki Kato
-
Publication number: 20160333113Abstract: Monoclonal antibodies against human and mouse tissue factor, and fragments thereof, are disclosed, as well as pharmaceutical compositions and compositions for drug delivery containing the same. Therapeutic methods using the same are also disclosed.Type: ApplicationFiled: February 3, 2015Publication date: November 17, 2016Applicants: NATIONAL CANCER CENTER, The University of Tokyo, RIKEN, NanoCarrier Co., Ltd.Inventors: Yasuhiro MATSUMURA, Masahiro YASUNAGA, Yoshikatsu KOGA, Yoshiyuki YAMAMOTO, Ryuta SATO, Ryo TSUMURA, Kazunori KATAOKA, Nobuhiro NISHIYAMA, Yutaka MIURA, Shino MANABE, Yasuki KATO
-
Patent number: 9415059Abstract: The present invention provides a particulate composition containing: block copolymer units being arranged radially with hydrophobic polymer-chain segments radially inside and hydrophilic polymer-chain segments radially outside; and a charged lipid which carries a charge opposite to the charge of a drug to be encapsulated, the charged lipid being attracted to the hydrophobic polymer-chain segment. In this particulate composition, the drug is retained within the particle via electrostatic binding with the charged lipid, whereby the outer surface of the particle is prevented from being charged to attract a substance which has a charge opposite to that of the charged lipid.Type: GrantFiled: August 31, 2010Date of Patent: August 16, 2016Assignee: Nanocarrier Co., Ltd.Inventors: Yasuki Kato, Atsushi Ishii
-
Patent number: 9278075Abstract: A composition of matter for use in encapsulating a drug is expressed by formula (1) or formula (2): wherein R1 and R2 are each independently a hydrogen atom or a substituted or unsubstituted, linear or branched alkyl group having 1 to 12 carbon atoms; A is a hydrophilic polymer chain; L1 and L3 are each a linking group; B is a cation-containing group; R3 is a side chain of an amino acid; z is an integer of 5 to 500; x is an integer of 40% or more of z; y is 0 or a positive integer; z-x-y is 0 or a positive integer; p is an integer of 1 to 10; and q is an integer of 1 to 10.Type: GrantFiled: January 16, 2012Date of Patent: March 8, 2016Assignees: NANOCARRIER CO., LTD., THE UNIVERSITY OF TOKYOInventors: Kazunori Kataoka, Ronald James Christie, Nobuhiro Nishiyama, Kanjiro Miyata, Shigeto Fukushima, Yu Matsumoto, Takahiro Nomoto, Yasuki Kato
-
Patent number: 9198860Abstract: The present invention provides a particulate pharmaceutical composition which has improved drug encapsulation stability and is suitable for a drug delivery system. The particulate pharmaceutical composition 1 contains: a plurality of block copolymer unit 2 arranged radially, each of which has a hydrophobic polymer-chain segment 2b, which is arranged radially inside, and a hydrophilic polymer-chain segment 2a, which is arranged radially outside; a drug 4, which includes a biomacromolecule; and a charged lipid 3, which has an electrical charge opposite to that of the drug 4; wherein the charged lipid 3 is being attracted to the hydrophobic polymer-chain segment 2b, and the drug 3 is positioned radially inside the hydrophobic polymer-chain segment 2b. The pharmaceutical composition 1 can effectively prevent the drug 4 from disengaging from the particle.Type: GrantFiled: February 14, 2011Date of Patent: December 1, 2015Assignee: NANOCARRIER CO., LTD.Inventors: Atsushi Ishii, Yasuki Kato
-
Patent number: 9114177Abstract: A block copolymer includes a polyamino acid chain segment and a hydrophilic polymer chain segment. The polyamino acid chain segment includes at least one amino acid residue having a side chain that contains a cationic group and at least one amino acid residue having a side chain that contains a substituted phenylboronic acid group. In the substituted phenylboronic acid group, at least one hydrogen of the phenyl ring is substituted so that the phenylboronic acid group has a pKa of less than 8. Such a block copolymer serves as a carrier that simultaneously imparts stability to a biotechnology-based drug in blood and provides suitable drug-releasing properties of the drug at an affected area.Type: GrantFiled: November 19, 2012Date of Patent: August 25, 2015Assignees: THE UNIVERSITY OF TOKYO, NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY, NANOCARRIER CO., LTD.Inventors: Kazunori Kataoka, Takehiko Ishii, Mitsuru Naito, Akira Matsumoto, Yasuki Kato
-
Publication number: 20150080454Abstract: A unit structure-type pharmaceutical composition includes at least one nucleic acid, such as siRNA, electrostatically bound to at least one block copolymer having a cationic polyamino acid segment and a hydrophilic polymer chain segment. The negative charge(s) of the nucleic acid are counterbalanced, at least substantially, by the positive charge(s) of the cationic polyamino acid segment such that the pharmaceutical composition is electrically neutral or nearly electrically neutral. Further, the nucleic acid is covered with the hydrophilic polymer chain segment(s). The at least one block copolymer thereby improves the blood retention capability of the nucleic acid(s).Type: ApplicationFiled: April 30, 2013Publication date: March 19, 2015Applicants: NANOCARRIER CO., LTD., THE UNIVERSITY OF TOKYOInventors: Kazunori Kataoka, Kanjiro Miyata, Nobuhiro Nishiyama, Kensuke Osada, Sumiyo Watanabe, Shigeto Fukushima, Hiroyuki Chaya, Hiroyasu Takemoto, Yasuki Kato
-
Publication number: 20150051347Abstract: A block copolymer includes a polyamino acid chain segment and a hydrophilic polymer chain segment. The polyamino acid chain segment includes at least one amino acid residue having a side chain that contains a cationic group and at least one amino acid residue having a side chain that contains a substituted phenylboronic acid group. In the substituted phenylboronic acid group, at least one hydrogen of the phenyl ring is substituted so that the phenylboronic acid group has a pKa of less than 8. Such a block copolymer serves as a carrier that simultaneously imparts stability to a biotechnology-based drug in blood and provides suitable drug-releasing properties of the drug at an affected area.Type: ApplicationFiled: November 19, 2012Publication date: February 19, 2015Applicants: THE UNIVERSITY OF TOKYO, NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY, NANOCARRIER CO., LTD.Inventors: Kazunori Kataoka, Takehiko Ishii, Mitsuru Naito, Akira Matsumoto, Yasuki Kato
-
Patent number: 8895076Abstract: A liquid composition containing a polymer micelle and having a pH values of 3.0 to 7.0 is provided. The micelle is constituted of a coordination compound having a block copolymer of polyethylene glycol and polyglutamic acid and cisplatin that is coordinate-bonded to the block copolymer.Type: GrantFiled: May 27, 2009Date of Patent: November 25, 2014Assignees: Nanocarrier Co., Ltd., The University of TokyoInventors: Kazunori Kataoka, Nobuhiro Nishiyama, Chieko Tsuchiya, Tatsuyuki Hayashi
-
Patent number: 8853167Abstract: The present invention provides a cationic polyamino acid suitable for a carrier that can form a stable complex with a nucleic acid under a physiological condition and release the nucleic acid in cells suitably. The cationic polyamino acid can associate with a nucleic acid and includes a cationic amino acid residue having a cationic group in a side chain and a hydrophobic amino acid residue having a hydrophobic group in a side chain. The cationic polyamino acid includes 1 to 20 units of the cationic amino acid residue and is represented by the following formula (1). The meaning of each symbol in the formula is as shown in the description.Type: GrantFiled: February 23, 2011Date of Patent: October 7, 2014Assignee: NanoCarrier Co., Ltd.Inventors: Yasuki Kato, Atsushi Ishii, Naoya Shibata, Tatsuyuki Hayashi, Kazunori Kataoka, Kanjiro Miyata, Nobuhiro Nishiyama
-
Publication number: 20140141072Abstract: Provided are a composition for preparing a lyophilized preparation, comprising a drug-encapsulating polymer micelle and saccharides and/or polyethylene glycol as a stabilizing agent, a lyophilized preparation and a process for producing them. The lyophilized preparation thus provided is easily restructured to an aqueous preparation using an aqueous medium.Type: ApplicationFiled: January 27, 2014Publication date: May 22, 2014Applicant: NANOCARRIER CO., LTD.Inventors: Yasuaki OGAWA, Shoko NAGASAKI, Yoshihiko NOGATA, Katsuhiko SAGAWA, Chieko TSUCHIYA
-
Publication number: 20140017328Abstract: A composition of matter for use in encapsulating a drug is expressed by formula (1) or formula (2): wherein R1 and R2 are each independently a hydrogen atom or a substituted or unsubstituted, linear or branched alkyl group having 1 to 12 carbon atoms; A is a hydrophilic polymer chain; L1 and L3 are each a linking group; B is a cation-containing group; R3 is a side chain of an amino acid; z is an integer of 5 to 500; x is an integer of 40% or more of z; y is 0 or a positive integer; z-x-y is 0 or a positive integer; p is an integer of 1 to 10; and q is an integer of 1 to 10.Type: ApplicationFiled: January 16, 2012Publication date: January 16, 2014Applicants: NANOCARRIER CO., LTD., THE UNIVERSITY OF TOKYOInventors: Kazunori Kataoka, Ronald James Christie, Nobuhiro Nishiyama, Kanjiro Miyata, Shigeto Fukushima, Yu Matsumoto, Takahiro Nomoto, Yasuki Kato
-
Publication number: 20140017192Abstract: A pharmaceutical composition includes a block copolymer having a hydrophilic segment, a hydrophobic segment, and a boronic acid compound bound to a side chain of the hydrophobic segment via a linker moiety that includes a heterocyclic structure. The heterocyclic structure contains a cyclic skeleton that includes a boron atom of the boronic acid compound, one or two atom(s) X bound to the boron atom and selected from an oxygen atom and a nitrogen atom, and one or two carbon atom(s) (respectively) bound to the atom(s) X. The block copolymer further includes at least one organic group bound to the carbon atom(s). The organic group(s) contain(s) an aromatic group or cyclic alkyl group that sterically protects a boronic acid ester bond and/or a boron amide bond resulting from bonding between the boron atom and the atom(s) X.Type: ApplicationFiled: April 2, 2012Publication date: January 16, 2014Applicant: NANOCARRIER CO., LTD.Inventors: Hiroyuki Saito, Katsutoshi Kobayashi, Ryosuke Tanaka, Mitsunori Harada, Yasuki Kato
-
Patent number: RE45471Abstract: A pharmaceutical composition or combination drug, which contains, as active ingredients, (a) a coordination compound composed of a block copolymer represented by the following formula I or formula II and cisplatin, and (b) gemcitabine hydrochloride. In the formulae I and II, R1, A, R2, R3, m and n are as defined in the description.Type: GrantFiled: March 3, 2014Date of Patent: April 14, 2015Assignee: Nanocarrier Co., Ltd.Inventors: Mitsunori Harada, Iulian Bobe, Takashi Shimizu